Scar – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：78頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Scar – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Scar - Pipeline Review, H2 2012', provides an overview of the Scar therapeutic pipeline. This report provides information on the therapeutic development for Scar, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Scar. 'Scar - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Scar.
- A review of the Scar products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Scar pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Scar.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Scar therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Scar - Pipeline Review, H2 2012', provides an overview of the Scar therapeutic pipeline. This report provides information on the therapeutic development for Scar, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Scar. 'Scar - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Scar.
- A review of the Scar products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Scar pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Scar.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Scar therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Scar Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Scar 9
Scar Therapeutics under Development by Companies 11
Scar Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Scar Therapeutics – Products under Development by Companies 18
Scar Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Scar Therapeutics Development 20
Renovo Group Plc 20
Garnet BioTherapeutics 21
Promedior, Inc. 22
Graceway Pharmaceuticals, LLC 23
GliaMed, Inc. 24
Excaliard Pharmaceuticals, Inc. 25
Easton Pharmaceuticals Inc. 26
Fibrocell Sciences, Inc. 27
Beech Tree Labs, Inc. 28
Scar – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
EXC 001 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AZX100 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PRM-151 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Laviv - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PXL01 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
RN1005 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Activin-Like Kinase 5 Inhibitor - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
GBT009 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Autologous Fibroblast Transplantation - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DSC127 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
RXI-109 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
TCA - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Autologous Fibroblasts - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Botulinum Toxin Type A - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Botox - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
FibroStem - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
EP-003 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Product Description 58
Mechanism of Action 58
R&D Progress 58
Scar Therapeutics – Drug Profile Updates 59
Scar Therapeutics – Discontinued Products 68
Scar Therapeutics - Dormant Products 69
Scar – Product Development Milestones 70
Featured News & Press Releases 70
Jul 10, 2012: Pergamum Reports Results From Phase II Trial Of PXL-01 For Prevention Of Post-Surgical Adhesions 70
Jun 26, 2012: RXi Pharma Announces Initiation Of First Clinical Trial Of RXI-109 70
May 31, 2012: RXi Pharma Receives FDA Clearance To Begin Clinical Trial With RXI-109 71
May 14, 2012: Fibrocell Submits Phase II Study Protocol To FDA To Evaluate Use Of Azficel-T To Treat Restrictive Burn Scars 72
Feb 10, 2012: Pergamum Completes Patient Recruitment In Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions 72
Nov 29, 2011: RegeneRx Receives Notice Of Allowance On US Patent For Skin Protection And Repair 72
Apr 27, 2011: Capstone Therapeutics Confirms Early Signal Of AZX100 Effect Based On Final Results Of Phase IIa Pilot Clinical Trial In Surgical Scarring 73
Apr 04, 2011: Capstone Therapeutics Announces Update To Timing Of Release Of Final Results From AZX100 Phase IIa Pilot Clinical Trial In Surgical Scarring 74
Feb 14, 2011: Pergamum To Extend Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions 75
Feb 03, 2011: RXi Pharmaceuticals Initiates Development Program For Dermal Anti-Scarring Product Candidate 75
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78
List of Tables
Number of Products Under Development for Scar, H2 2012 9
Products under Development for Scar – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Renovo Group Plc, H2 2012 20
Garnet BioTherapeutics, H2 2012 21
Promedior, Inc., H2 2012 22
Graceway Pharmaceuticals, LLC, H2 2012 23
GliaMed, Inc., H2 2012 24
Excaliard Pharmaceuticals, Inc., H2 2012 25
Easton Pharmaceuticals Inc., H2 2012 26
Fibrocell Sciences, Inc., H2 2012 27
Beech Tree Labs, Inc., H2 2012 28
Assessment by Monotherapy Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
Scar Therapeutics – Drug Profile Updates 59
Scar Therapeutics – Discontinued Products 68
Scar Therapeutics – Dormant Products 69
List of Figures
Number of Products under Development for Scar, H2 2012 9
Products under Development for Scar – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Scar Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Scar 9
Scar Therapeutics under Development by Companies 11
Scar Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Scar Therapeutics – Products under Development by Companies 18
Scar Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Scar Therapeutics Development 20
Renovo Group Plc 20
Garnet BioTherapeutics 21
Promedior, Inc. 22
Graceway Pharmaceuticals, LLC 23
GliaMed, Inc. 24
Excaliard Pharmaceuticals, Inc. 25
Easton Pharmaceuticals Inc. 26
Fibrocell Sciences, Inc. 27
Beech Tree Labs, Inc. 28
Scar – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
EXC 001 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AZX100 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PRM-151 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Laviv - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PXL01 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
RN1005 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Activin-Like Kinase 5 Inhibitor - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
GBT009 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Autologous Fibroblast Transplantation - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DSC127 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
RXI-109 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
TCA - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Autologous Fibroblasts - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Botulinum Toxin Type A - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Botox - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
FibroStem - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
EP-003 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Product Description 58
Mechanism of Action 58
R&D Progress 58
Scar Therapeutics – Drug Profile Updates 59
Scar Therapeutics – Discontinued Products 68
Scar Therapeutics - Dormant Products 69
Scar – Product Development Milestones 70
Featured News & Press Releases 70
Jul 10, 2012: Pergamum Reports Results From Phase II Trial Of PXL-01 For Prevention Of Post-Surgical Adhesions 70
Jun 26, 2012: RXi Pharma Announces Initiation Of First Clinical Trial Of RXI-109 70
May 31, 2012: RXi Pharma Receives FDA Clearance To Begin Clinical Trial With RXI-109 71
May 14, 2012: Fibrocell Submits Phase II Study Protocol To FDA To Evaluate Use Of Azficel-T To Treat Restrictive Burn Scars 72
Feb 10, 2012: Pergamum Completes Patient Recruitment In Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions 72
Nov 29, 2011: RegeneRx Receives Notice Of Allowance On US Patent For Skin Protection And Repair 72
Apr 27, 2011: Capstone Therapeutics Confirms Early Signal Of AZX100 Effect Based On Final Results Of Phase IIa Pilot Clinical Trial In Surgical Scarring 73
Apr 04, 2011: Capstone Therapeutics Announces Update To Timing Of Release Of Final Results From AZX100 Phase IIa Pilot Clinical Trial In Surgical Scarring 74
Feb 14, 2011: Pergamum To Extend Phase II Clinical Trial For Prevention Of Post-Surgical Adhesions 75
Feb 03, 2011: RXi Pharmaceuticals Initiates Development Program For Dermal Anti-Scarring Product Candidate 75
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78
List of Tables
Number of Products Under Development for Scar, H2 2012 9
Products under Development for Scar – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Renovo Group Plc, H2 2012 20
Garnet BioTherapeutics, H2 2012 21
Promedior, Inc., H2 2012 22
Graceway Pharmaceuticals, LLC, H2 2012 23
GliaMed, Inc., H2 2012 24
Excaliard Pharmaceuticals, Inc., H2 2012 25
Easton Pharmaceuticals Inc., H2 2012 26
Fibrocell Sciences, Inc., H2 2012 27
Beech Tree Labs, Inc., H2 2012 28
Assessment by Monotherapy Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
Scar Therapeutics – Drug Profile Updates 59
Scar Therapeutics – Discontinued Products 68
Scar Therapeutics – Dormant Products 69
List of Figures
Number of Products under Development for Scar, H2 2012 9
Products under Development for Scar – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33
